Elske Hoitsma
Leiderdorp, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Treatment satisfaction during personalized extended interval dosing of natalizumab in patients with multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: April 30, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.
Journal: European journal of neurology
Published: March 19, 2026
Real world drug utilization patterns in the first years following a relapsing-remitting multiple sclerosis diagnosis.
Journal: Multiple sclerosis and related disorders
Published: August 31, 2025
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).
Journal: Journal of neurology
Published: June 16, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 31, 2024
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.
Journal: JAMA neurology
Published: December 09, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 04, 2024
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
Journal: Journal of the neurological sciences
Published: March 15, 2024
Longitudinal determinants of employment status in people with relapsing-remitting multiple sclerosis.
Journal: IBRO neuroscience reports
Published: February 25, 2024
Reliability parameters of the Timed 25-Foot-Walk (T25FW) in patients with Multiple Sclerosis: Lower walking speed is associated with greater Smallest Detectable Change.
Journal: Multiple sclerosis and related disorders
Published: February 16, 2024
The feasibility and usability of a personal health record for patients with multiple sclerosis: a 2-year evaluation study.
Journal: Frontiers in human neuroscience
Published: January 31, 2024
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: June 29, 2023
Last Updated: 09/26/2026